Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 6/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805106 | 1.00 | KDM4E (0.46) | KDM4ESCN10ABACE1NPBWR1PDE2A | |
| SCHEMBL789144 | 0.84 | KDM4E (0.45) | KDM4ESCN10ABACE1PDE2ADHFR | |
| SCHEMBL788374 | 0.84 | KDM4E (0.45) | KDM4ESCN10ABACE1PDE2ADHFR | |
| SCHEMBL10111749 | 0.83 | KDM4E (0.50) | KDM4EBACE1NPBWR1PDE2APDE10A | |
| SCHEMBL10111725 | 0.83 | KDM4E (0.50) | KDM4EBACE1NPBWR1PDE2APDE10A | |
| SCHEMBL20248267 | 0.82 | DHFR (0.44) | KDM4EDHFR | |
| SCHEMBL20248263 | 0.82 | DHFR (0.44) | KDM4EDHFR | |
| SCHEMBL22369922 | 0.82 | KDM4E (0.43) | KDM4ESCN10ABACE1NPBWR1GAK | |
| SCHEMBL805013 | 0.80 | KDM4E (0.42) | KDM4EPDE10ATSHR | |
| SCHEMBL10111820 | 0.80 | SCN10A (0.40) | SCN10APDE2APDE10ADHFRPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | PREP, PRSS1, PEPD | KDM4E 1290/4885SCN10A 3186/4885BACE1 553/4885 |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | KDM4E 1290/4885SCN10A 3186/4885BACE1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.